Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Passiglia

Showing results (21-30 of 127) with videos related to

Pageof 13
Sort By:
Life (Basel, Switzerland)|June 28, 2023
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare SubtypesAndrea Mogavero, Paolo Bironzo, Luisella Righi, et al.
PPAR Research|February 10, 2017
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling PathwayLaura La Paglia, Angela Listì, Stefano Caruso, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 8, 2023
Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumoursDaphne W Dumoulin, Paolo Bironzo, Francesco Passiglia, et al.
Expert Opinion on Drug Safety|November 21, 2018
Monoclonal antibodies for the treatment of non-hematological tumors: a safety reviewLidia Rita Corsini, Daniele Fanale, Francesco Passiglia, et al.
International Journal of Molecular Sciences|May 27, 2023
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic StrategiesMassimiliano Cani, Valerio Maria Napoli, Edoardo Garbo, et al.
Clinical Lung Cancer|September 12, 2020
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study DesignFrancesco Passiglia, Paolo Bironzo, Luisella Righi, et al.
Frontiers in Medicine|March 16, 2017
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of NintedanibLuis Corrales, Amanda Nogueira, Francesco Passiglia, et al.
Expert Review of Gastroenterology & Hepatology|June 25, 2014
The role of targeted therapy for gastrointestinal tumorsChristian Rolfo, Giuseppe Bronte, Giovanni Sortino, et al.
Critical Reviews in Oncology/Hematology|August 12, 2018
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selectionGiuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective TrialFrancesco Passiglia, Luisella Righi, Paolo Bironzo, et al.
Pageof 13

Showing results (21-30 of 127) with videos related to

Sort By:
Pageof 13
Life (Basel, Switzerland)|June 28, 2023
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare SubtypesAndrea Mogavero, Paolo Bironzo, Luisella Righi, et al.
PPAR Research|February 10, 2017
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling PathwayLaura La Paglia, Angela Listì, Stefano Caruso, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 8, 2023
Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumoursDaphne W Dumoulin, Paolo Bironzo, Francesco Passiglia, et al.
Expert Opinion on Drug Safety|November 21, 2018
Monoclonal antibodies for the treatment of non-hematological tumors: a safety reviewLidia Rita Corsini, Daniele Fanale, Francesco Passiglia, et al.
International Journal of Molecular Sciences|May 27, 2023
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic StrategiesMassimiliano Cani, Valerio Maria Napoli, Edoardo Garbo, et al.
Clinical Lung Cancer|September 12, 2020
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study DesignFrancesco Passiglia, Paolo Bironzo, Luisella Righi, et al.
Frontiers in Medicine|March 16, 2017
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of NintedanibLuis Corrales, Amanda Nogueira, Francesco Passiglia, et al.
Expert Review of Gastroenterology & Hepatology|June 25, 2014
The role of targeted therapy for gastrointestinal tumorsChristian Rolfo, Giuseppe Bronte, Giovanni Sortino, et al.
Critical Reviews in Oncology/Hematology|August 12, 2018
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selectionGiuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective TrialFrancesco Passiglia, Luisella Righi, Paolo Bironzo, et al.
Pageof 13